Utilizing glioblastoma stem cells (GSCs) and xenograft mice, MA2, the ethyl ester form of meclofenamic acid (MA), an FDA-approved non-steroidal anti-inflammatory drug, was identified as a selective inhibitor of FTO that increases m6A mRNA levels and suppresses GSC-initiated tumor progression [105, 106]. This evidence concerns the gene FTO and neoplasm.